Join to access to all OVN content. Join Now

Results for 'Biosimilars'

...
OVN Avatar Jorge J. García, Luis E. Raez, Daniel Rosas
A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation

Aug 3rd • 10 mins read

...
OVN Avatar Vishwanath Sathyanarayanan, MD, DM, Christopher R. Flowers, MD, MSc, and Swaminathan P. Iyer, MD, MBBS
Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States

Jul 21st • 12 mins read

...
OVN Avatar Cornelius F Waller & Adriano Friganovi´c
Biosimilars in oncology: key role of nurses in patient education

Jun 15th • 10 mins read

...
OVN Avatar Mark Verrill, Paul Declerck, Sibylle Loibl, Jake Lee & Javier Cortes
The rise of oncology biosimilars: from process to promise

Aug 23rd • 18 mins read

...
OVN Avatar YuQian Liu, PharmD
Uptake of Oncology Biosimilars: Managed Care Strategies to Improve Value-Based Care Systems

Jul 7th • 25 mins read

...
OVN Avatar Rinda Devi Bachu, Mariam Abou-Dahech, Swapnaa Balaji, Sai H. S. Boddu, Samson Amos, Vishal Singh, R. Jayachandra Babu, Amit K. Tiwari
Oncology biosimilars: New developments and future directions

Nov 25th • 30 mins read

...
OVN Avatar John Hair, Thomas Maryon, and Cristian Lieneck
Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption

Oct 27th • 30 mins read

...
OVN Avatar Deeksha Joshi, Rubiya Khursheed, Saurabh Gupta, Diksha Wadhwa, Thakur Gurjeet Singh, Sumit Sharma, Sejal Porwal, Swati Gauniyal, Sukriti Vishwas, Sanjay Goyal, Gaurav Gupta, Rajaraman D. Eri, Kylie A. Williams, Kamal Dua, Sachin Kumar Singh
Biosimilars in Oncology: Latest Trends and Regulatory Status

Dec 5th • 20 mins read

...
OVN Avatar Gregory S. Calip, PharmD, MPH, PhD, Ivy P. Altomare, MD, Jenny S. Guadamuz, MSPH, PhD
Evaluating External Validity of Oncology Biosimilar Safety Studies

Apr 6th • 2 mins read

...
OVN Avatar Qiyou Wu, Zhiwei Lian, Xin Wang, Hanchao Cheng, Jing Sun, Hui Yu, Gong Zhang, Fan Wu, Jian Liu and Chuanben Chen
Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China

Jan 12th • 13 mins read

...
OVN Avatar John Devin Peipert, PhD, Karen Kaiser, PhD, Sheetal Kircher, MD, George J. Greene, PhD, Sara Shaunfield, PhD, Katherina Hauner, PhD, David Cella, PhD, and Daniel K. Mroczek, PhD
Medical Oncologists’ Knowledge and Perspectives on the Use of Biosimilars in the United States

Jan 9th • 9 mins read

...
OVN Avatar Chad Williamson, MBA, MS Leanne Berger, BS, Thomas P. Sullivan, BS SHOW
Addressing oncologists' gaps in the use of biosimilar products

Jun 19th • 5 mins read

...
OVN Avatar Marc Thill, Nicholas Thatcher, Vladimir Hanes & Gary H. Lyman
Biosimilars: what the oncologist should know

Dec 18th • 25 mins read

...
OVN Avatar Carina Dolan, PharmD, BCOP
Opportunities and challenges in biosimilar uptake in oncology

Jun 26th • 7 mins read